Abstract library

122 results for "molecular".
#491 International Survey for the Use of Biomarkers and Molecular Imaging in Neuroendocrine Tumors (NET): What we are Using in Daily Practice
Introduction: Several guidelines have given recommendations for optimal use of biomarkers and molecular imaging. However, those guidelines’ implementation may not be always possible due to local policies or lack of access to several diagnostic studies.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: DR CHRISTOS Toumpanakis
#195 UMB-4 as New Monoclonal Somatostatin Receptor Antibody: Correlation of Immunostaining with Molecular Imaging using Somatostatin Receptor PET/CT
Introduction: Somatostatin receptors (SSTR) are known for an overexpression in neuroendocrine tumors (NET).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Daniel Kaemmerer
Authors: Kaemmerer D, Peter L, Lupp A, Schulz S, ...
#26 Molecular imaging of gastroenteropancreatic neuroendocrine tumours with Ga-68 DOTANOC PET/CT and correlation with an immunhistochemical quantification of somatostatin receptors using novel monoclonal and polyclonal antibodies
Introduction: Receptor PET/CT with somatostatin analogues marked with Gallium-68 (SMS-R-PET/CT) is currently the golden standard in diagnosing gastroenteropancreatic neuroendocrine tumors (GEP-NET), which are known for an overexpression of somatostatin receptors (SSTRs).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Daniel Kaemmerer
#310 Relationship Between Dose and Molecular Response After Peptide Receptor Radionuclide Therapy (PRRNT) in Neuroendocrine Tumors: Preliminary Results
Introduction: PRRNT is an effective therapy option in well-differentiated neuroendocrine tumors. However, there exists no study showing the ability to predict response to PRRNT on a pretherapy Ga-68 SMS-R PET/CT.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Prof. Dr. med. Richard P Baum
Keywords: dose, molecular, response
#863 Assessment of Neuroendocrine Tumors' Heterogeneity with Combination of Molecular Imaging Studies
Introduction: Neuroendocrine tumors (NET) are heterogeneous neoplasms. The choice of the appropriate molecular imaging study for assessment of disease extent usually depends on tumor grade.
Conference: 11th Annual ENETS Conference (2014)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD Roberta E Rossi
#733 Analysis of Predictive Markers of Response to Chemotherapy in Microdissected Components of Mixed Neuroendocrine/non-Neuroendocrine Carcinomas
Introduction: Mixed neuroendocrine (NE)/non-NE carcinomas lack pathological or molecular prognostic or predictive markers.
Conference: 10th Annual ENETS Conference (2013)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Marco Volante
#1059 Genomic Profiling of Metastatic Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients in Precision-Medicine Era
Introduction: We have conducted molecular profiling through high-throughput molecular test as part of clinical practice for patients with advanced gastrointestinal (GI) cancer, or rare cancer including gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Conference: 12th Annual ENETS Conference (2015)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Seung Kim
Authors: Kim S, Yoo K, Jung K, Lee S, ...
#2108 Molecular Characterization of Primary and Metastatic Pancreatic Neuroendocrine Tumors
Introduction: Pancreatic neuroendocrine tumours (PNETs) are a heterogeneous group of rare pancreatic neoplasms often diagnosed with distant metastases, which are associated with significantly poorer prognosis. Recurrent somatic mutations, chromosomal aberrations and gene expression signatures in PNETs have been described, but the clinical significance of these molecular changes is still poorly understood, and the clinical outcomes of PNET patients remain highly variable.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Chi-Fu Kevin Yang
Authors: Yang K C, Wong H L, Shen Y, Colborne S, ...
#2215 Development of Multiplex Biomarker Assay to Subtype Pancreatic Neuroendocrine Tumors (PanNETs) with Distinct Prognosis and Mutations
Introduction: Overall 5-year survival for PanNETs ranges from 25-100%. The treatment paradigm for PanNETs largely based upon grades, which is significantly heterogeneous. We previously defined three molecular subtypes (distributed grades) of PanNETs using PanNETassigner signature. There is an unmet clinical need for prognostic and predictive biomarkers and clinically-relevant assays to complement grade and improve patient stratification.
Conference: 15th Annual ENETS conference (2018)
Category: Biomarkers
Presenting Author: Dr Anguraj Sadanandam
#772 Role of Molecular Imaging using Ga-68 Somatostatin-Receptor PET/CT in Predicting Survival after Peptide Receptor Radionuclide Therapy of Neuroendocrine Neoplasms
Introduction: Peptide receptor radionuclide therapy (PRRNT) is valuable for the management of metastasized and/or inoperable neuroendocrine neoplasms (NENs).
Conference: 10th Annual ENETS Conference (2013)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Dr. Harshad Kulkarni